Articles tagged with Cancer Immunotherapy
A phase 1b immunotherapy trial combining nivolumab and ipilimumab has shown high one-year and two-year overall survival rates of 94% and 88%, respectively, in advanced melanoma patients. The treatment regimen has demonstrated long-lasting benefits for these patients.
Dr. Robert D. Schreiber receives AACR-CRI Lloyd J. Old Award in Cancer Immunology for his groundbreaking contributions to the field of cancer immunology, including identifying IFNγ as a key cytokine and developing the cancer immunoediting concept.
Researchers at Fred Hutchinson Cancer Research Center used Droplet Digital PCR to quantify tumor-infiltrating T-lymphocytes (TILs), a subpopulation of immune cells that improve cancer survival. Higher TIL levels correlate positively with patient survival, suggesting an active role in suppressing tumor formation. The study paves the way...
Dr. Rodriguez's award-winning research identified a potential new therapeutic approach to make T cells resistant to tumor suppression, enhancing anti-tumor activity and overcoming immune suppression. His findings suggest Notch-1 may be an effective new approach for T cell-based immunotherapy.
Researchers at Moffitt Cancer Center have developed a synthetic vaccine that induces tumor clearance in 100% of mice with HPV16-induced tumors. The vaccine, called TriVax-HPV, generates large numbers of cytotoxic T-cells targeting viral proteins, offering an alternative to conventional therapies for cervical cancer.
A new phase III study comparing the efficacy of Bacillus Calmette Guérin strains Tice and Connaught for non-muscle invasive bladder cancer treatment found that Connaught significantly reduced cancer recurrence rates, with a five-year recurrence-free survival rate of 75% compared to 46% for Tice. The study has the potential to shift the...
Researchers at Penn State College of Medicine found a way to generate antigen-specific T cells using induced pluripotent stem (iPS) cells, which could lead to a simpler and more efficient method for using the body's immune system to fight cancer. The study, published in Cancer Research, used iPS cells from mice converted into immune ce...
Researchers have developed a new microchip that can quickly and inexpensively assess immune function by examining biomarkers from single cells. The technology has the potential to be used routinely to monitor immune system performance and evaluate the effectiveness of certain classes of therapeutics, such as vaccines and immunotherapies.
The Fred Hutchinson Cancer Research Center will lead the Cancer Immunotherapy Trials Network (CITN), a multicenter research network on promising new agents that boost patients' immune systems. The CITN aims to develop treatments for cancer by selecting, designing and conducting early-phase trials using priority agents.
Researchers propose new clinical trial endpoints for immunotherapies, accounting for delayed responses and novel patterns of anti-tumor activity. The immune-related response criteria (irRC) offer a revised approach to measuring treatment success, considering factors such as lymphocyte infiltration and tumor burden.
Stat3 promotes pro-cancer immune responses and inhibits antitumor immunity by stimulating immunosuppressive factors and inhibiting expression of chemicals critical for antitumor immunity. The study reveals a mechanism by which oncogenic pathways regulate the immune microenvironment to promote tumor development.
Researchers discovered that bone marrow-derived dendritic cells (BM-DCs) pulsed with tumor lysates can stimulate T cells to attack and kill gastric cancer cells. This finding suggests a potential new approach for treating advanced gastric cancer.
Researchers at OHSU Cancer Institute discovered that combining stereotactic body radiation therapy (SBRT) with immunotherapy significantly increases the efficacy of treating lung cancer. The study found that SBRT helped to activate more 'killer' immune cells, leading to better tumor clearance.
Researchers have discovered that the immune system can enter a dormant state with cancer cells, controlling their growth without eliminating them. This finding may lead to alternative treatments for cancer, such as using immunotherapy to induce equilibrium and convert cancers into chronic but controllable diseases.
GSK has launched a Phase III trial evaluating its novel immunotherapy MAGE-A3 ASCI in patients with stage IB or II NSCLC. The trial aims to assess the efficacy and safety of MAGE-A3 ASCI as adjuvant therapy following surgery.
Researchers found that hematopoietic stem cell transplantation enhanced the expansion of tumor-reactive CD8+ T cells, leading to increased tumor regression. The study suggests that this approach may improve treatment regimens for cancer patients.